Compare · CMMB vs IVA
CMMB vs IVA
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Inventiva S.A. (IVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and IVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IVA is the larger of the two at $790.0M, about 62.8x CMMB ($12.6M).
- Over the past year, CMMB is down 65.1% and IVA is up 8.7% - IVA leads by 73.7 points.
- IVA has been more active in the news (14 items in the past 4 weeks vs 3 for CMMB).
- IVA has more recent analyst coverage (16 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Inventiva S.A.
- Price
- $1.69-3.43%
- $3.83+0.79%
- Market cap
- $12.6M
- $790.0M
- 1M return
- -10.58%
- -33.16%
- 1Y return
- -65.08%
- +8.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 3
- 14
- Recent ratings
- 5
- 16
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Latest CMMB
- SEC Form 3 filed by new insider Melincoff Gwen A
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Mor George Adi
- SEC Form 3 filed by new insider Darvish Nissim
- SEC Form 3 filed by new insider Cohen Neil Harris
Latest IVA
- SEC Form 6-K filed by Inventiva S.A.
- Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
- SEC Form 6-K filed by Inventiva S.A.
- SEC Form 6-K filed by Inventiva S.A.
- SEC Form 424B5 filed by Inventiva S.A.
- SEC Form FWP filed by Inventiva S.A.
- Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
- Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
- SEC Form F-3ASR filed by Inventiva S.A.
- Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris